A private nuclear microreactor reaches criticality in the United States

The United States Department of Energy said a nuclear microreactor developed by a private company had reached criticality for the first time. The announcement sat under a program to develop the nuclear industry in the second Trump administration. Criticality was the milestone the department reported, not a claim of commercial electricity already on the grid.

The same week North Korea unveiled a facility it said would produce nuclear-weapon fuel. That was a weapons-fuel plant, not a civilian power reactor. It was a separate nuclear story from the American microreactor.

Cambridge and DIOSynVax reported a first human trial of an AI-designed vaccine aimed at coronaviruses including SARS, MERS, and COVID-19, and potentially Ebola. The technology point was the use of AI in the vaccine design. The trial was the step that made the announcement more than a laboratory claim.

No public output figure, in megawatts or doses, was paired with the microreactor's criticality in the day's report. The fact was the first criticality under that program. Readers were not given a construction timeline beyond the announcement.

North Korea's plant and the American reactor pointed in different directions, one toward weapon fuel and one toward an industry program. They were both nuclear headlines in the first week of June. Neither was described as part of the Iran talks.

The vaccine trial added a biomedical use of new computing to the same technology list. It did not replace the microreactor story. It showed the week's science items ranging from reactors to a first-in-human study.